Bank of America
CAPR icon

Bank of America’s Capricor Therapeutics CAPR Stock Holding History

Bank of America’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$993 – 8332
2025
Q2 		$993 Buy
+100
New +$1.06K ﹤0.01% 7531

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America's CAPR Position: Q1 2026 in Review

Bank of America increased its Capricor Therapeutics (CAPR) stake by 672% in Q1 2026, buying an estimated $9.64M and bringing the position to 415,483 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2776.

Bank of America first reported a position in CAPR in Q1 2016 and has held it in 36 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Bank of America held 415,483 shares of Capricor Therapeutics worth $12.6M as of Q1 2026.
  • Bank of America bought 361,664 Capricor Therapeutics shares in Q1 2026, an estimated $9.64M.
  • Capricor Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2776 holding.
  • Bank of America first reported a position in Capricor Therapeutics in Q1 2016 and has held it in 36 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.